Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.
University of Malaya, Kuala Lumpur, Malaysia.
JAMA. 2019 May 14;321(18):1788-1798. doi: 10.1001/jama.2019.4783.
Unrecognized obstructive sleep apnea increases cardiovascular risks in the general population, but whether obstructive sleep apnea poses a similar risk in the perioperative period remains uncertain.
To determine the association between obstructive sleep apnea and 30-day risk of cardiovascular complications after major noncardiac surgery.
DESIGN, SETTING, AND PARTICIPANTS: Prospective cohort study involving adult at-risk patients without prior diagnosis of sleep apnea and undergoing major noncardiac surgery from 8 hospitals in 5 countries between January 2012 and July 2017, with follow-up until August 2017. Postoperative monitoring included nocturnal pulse oximetry and measurement of cardiac troponin concentrations.
Obstructive sleep apnea was classified as mild (respiratory event index [REI] 5-14.9 events/h), moderate (REI 15-30), and severe (REI >30), based on preoperative portable sleep monitoring.
The primary outcome was a composite of myocardial injury, cardiac death, heart failure, thromboembolism, atrial fibrillation, and stroke within 30 days of surgery. Proportional-hazards analysis was used to determine the association between obstructive sleep apnea and postoperative cardiovascular complications.
Among a total of 1364 patients recruited for the study, 1218 patients (mean age, 67 [SD, 9] years; 40.2% women) were included in the analyses. At 30 days after surgery, rates of the primary outcome were 30.1% (41/136) for patients with severe OSA, 22.1% (52/235) for patients with moderate OSA, 19.0% (86/452) for patients with mild OSA, and 14.2% (56/395) for patients with no OSA. OSA was associated with higher risk for the primary outcome (adjusted hazard ratio [HR], 1.49 [95% CI, 1.19-2.01]; P = .01); however, the association was significant only among patients with severe OSA (adjusted HR, 2.23 [95% CI, 1.49-3.34]; P = .001) and not among those with moderate OSA (adjusted HR, 1.47 [95% CI, 0.98-2.09]; P = .07) or mild OSA (adjusted HR, 1.36 [95% CI, 0.97-1.91]; P = .08) (P = .01 for interaction). The mean cumulative duration of oxyhemoglobin desaturation less than 80% during the first 3 postoperative nights in patients with cardiovascular complications (23.1 [95% CI, 15.5-27.7] minutes) was longer than in those without (10.2 [95% CI, 7.8-10.9] minutes) (P < .001). No significant interaction effects on perioperative outcomes were observed with type of anesthesia, use of postoperative opioids, and supplemental oxygen therapy.
Among at-risk adults undergoing major noncardiac surgery, unrecognized severe obstructive sleep apnea was significantly associated with increased risk of 30-day postoperative cardiovascular complications. Further research would be needed to assess whether interventions can modify this risk.
在普通人群中,未被识别的阻塞性睡眠呼吸暂停会增加心血管风险,但阻塞性睡眠呼吸暂停是否会在围手术期带来类似的风险仍不确定。
确定阻塞性睡眠呼吸暂停与主要非心脏手术后 30 天内心血管并发症风险之间的关系。
设计、地点和参与者:这是一项前瞻性队列研究,纳入了来自 5 个国家 8 家医院的无睡眠呼吸暂停既往诊断且正在接受主要非心脏手术的高危患者,随访至 2017 年 8 月。术后监测包括夜间脉搏血氧饱和度和肌钙蛋白浓度测量。
阻塞性睡眠呼吸暂停根据术前便携式睡眠监测分为轻度(呼吸事件指数 [REI] 5-14.9 次/小时)、中度(REI 15-30)和重度(REI >30)。
主要结局为术后 30 天内心肌损伤、心脏死亡、心力衰竭、血栓栓塞、心房颤动和中风的复合事件。采用比例风险分析来确定阻塞性睡眠呼吸暂停与术后心血管并发症之间的关系。
在这项共纳入 1364 例患者的研究中,1218 例患者(平均年龄 67 [标准差 9] 岁;40.2%为女性)纳入了分析。术后 30 天,主要结局的发生率分别为:重度阻塞性睡眠呼吸暂停患者为 30.1%(41/136),中度阻塞性睡眠呼吸暂停患者为 22.1%(52/235),轻度阻塞性睡眠呼吸暂停患者为 19.0%(86/452),无阻塞性睡眠呼吸暂停患者为 14.2%(56/395)。阻塞性睡眠呼吸暂停与主要结局风险增加相关(调整后的危险比 [HR],1.49 [95%CI,1.19-2.01];P=0.01);然而,这种关联仅在重度阻塞性睡眠呼吸暂停患者中显著(调整后的 HR,2.23 [95%CI,1.49-3.34];P=0.001),而在中度阻塞性睡眠呼吸暂停患者(调整后的 HR,1.47 [95%CI,0.98-2.09];P=0.07)或轻度阻塞性睡眠呼吸暂停患者(调整后的 HR,1.36 [95%CI,0.97-1.91];P=0.08)中并不显著(P=0.01 用于交互作用)。发生心血管并发症患者在术后第 1-3 个夜晚的平均累计低氧血红蛋白饱和度时间(23.1 [95%CI,15.5-27.7] 分钟)长于无心血管并发症患者(10.2 [95%CI,7.8-10.9] 分钟)(P<0.001)。麻醉类型、术后阿片类药物使用和补充氧气治疗对围手术期结局均无显著的交互作用效应。
在接受主要非心脏手术的高危成年人中,未被识别的重度阻塞性睡眠呼吸暂停与术后 30 天内心血管并发症风险增加显著相关。需要进一步研究评估干预措施是否可以改变这种风险。